Financial Survey: MyMD Pharmaceuticals (MYMD) and Its Peers

MyMD Pharmaceuticals (NASDAQ:MYMDGet Rating) is one of 40 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare MyMD Pharmaceuticals to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, risk, dividends and profitability.


This table compares MyMD Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MyMD Pharmaceuticals N/A -77.76% -69.92%
MyMD Pharmaceuticals Competitors -2,615.40% -73.84% -34.36%

Analyst Ratings

This is a summary of recent ratings and target prices for MyMD Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MyMD Pharmaceuticals 0 0 0 0 N/A
MyMD Pharmaceuticals Competitors 200 545 1145 18 2.51

As a group, “Diagnostic substances” companies have a potential upside of 73.33%. Given MyMD Pharmaceuticals’ rivals higher possible upside, analysts clearly believe MyMD Pharmaceuticals has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

12.4% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 49.2% of shares of all “Diagnostic substances” companies are held by institutional investors. 11.3% of MyMD Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

MyMD Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals’ rivals have a beta of 1.40, meaning that their average share price is 40% more volatile than the S&P 500.

Valuation & Earnings

This table compares MyMD Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MyMD Pharmaceuticals $1.58 million -$29.89 million -5.98
MyMD Pharmaceuticals Competitors $411.38 million $32.43 million -65.52

MyMD Pharmaceuticals’ rivals have higher revenue and earnings than MyMD Pharmaceuticals. MyMD Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


MyMD Pharmaceuticals rivals beat MyMD Pharmaceuticals on 7 of the 10 factors compared.

About MyMD Pharmaceuticals

(Get Rating)

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with's FREE daily email newsletter.